Asset Details
Do you wish to reserve the book?
Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
Do you wish to request the book?
Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
2016
Overview
CD137(4-1BB) costimulation and adoptive T cell therapy strongly synergize in terms of achieving maximal efficacy against experimental cancers. These costimulatory biological functions of CD137 have been exploited by means of introducing the CD137 signaling domain in clinically successful chimeric antigen receptors and to more efficiently expand T cells in culture. In addition, immunomagnetic sorting of CD137-positive T cells among tumor-infiltrating lymphocytes selects for the fittest antitumor T lymphocytes for subsequent cultures. In mouse models, co-infusion of both agonist antibodies and T cells attains marked synergistic effects that result from more focused and intense cytolytic activity visualized under in vivo microscopy and from more efficient entrance of T cells into the tumor through the vasculature. These several levels of dynamic interaction between adoptive T cell therapy and CD137 offer much opportunity to raise the efficacy of current cancer immunotherapies.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Animals
/ Antibodies, Monoclonal - immunology
/ Antibodies, Monoclonal - therapeutic use
/ Humans
/ Immunotherapy, Adoptive - methods
/ Lymphocytes, Tumor-Infiltrating - immunology
/ Lymphocytes, Tumor-Infiltrating - metabolism
/ Lymphocytes, Tumor-Infiltrating - transplantation
/ Medicine
/ Oncology
/ T-Lymphocytes - transplantation
/ T-Lymphocytes, Cytotoxic - immunology
/ T-Lymphocytes, Cytotoxic - metabolism
/ T-Lymphocytes, Cytotoxic - transplantation
/ Tumor Necrosis Factor Receptor Superfamily, Member 9 - immunology
/ Tumor Necrosis Factor Receptor Superfamily, Member 9 - metabolism
